Hernexeos (zongertinib tablets) approved in China as first oral targeted therapy for previously treated patients with HER2-mutant advanced NSCLC – Boehringer
Boehringer Ingelheim’s Hernexeos (zongertinib tablets) has been approved as monotherapy by China’s National Medical Products Administration (NMPA) for the treatment of adult patients with unresectable, locally advanced or… read more.
